No Data
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Oppenheimer Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $52
Dianthus Therapeutics Price Target Raised to $52.00/Share From $48.00 by Oppenheimer
Dianthus Therapeutics Is Maintained at Outperform by Oppenheimer
Raymond James Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $56
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45
No Data
No Data